Spectrum Adds Shutdown To Deal Clock, Others Could Follow

Law360 (January 17, 2019, 9:33 PM EST) -- With the partial government shutdown in its fourth week, Spectrum Pharmaceuticals Inc. and Acrotech Biopharma LLC incorporated protection against the delay of required regulatory approvals into Thursday's announced contract for a drug portfolio sale, a move other dealmakers will likely follow even after the shutdown ends.

Spectrum announced a potential $300 million sale of a seven-therapy portfolio to Acrotech, a subsidiary of Aurobindo Pharma USA Inc. The deal comes with a caveat to the otherwise conventional 120-day “drop dead date” from signing by which it must be completed, giving the companies until mid-May.

Because a long shutdown could prevent the transaction...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!